CLINICAL USE

Beta2–adrenoceptor agonist: Reversible airways obstruction

DOSE IN NORMAL RENAL FUNCTION

Oral: 2.5–5 mg 3 times daily SC/IM/IV: 250–500 micrograms up to 4 times daily

IV infusion

: 90–300 micrograms/hour Turbohaler: 500 micrograms (1 inhalation) up to 4 times daily Nebulisation: 5–10 mg 2–4 times daily, or more frequently

PHARMACOKINETICS

  • Molecular weight                           : 548.6
  • %Protein binding                           : 15–25
  • %Excreted unchanged in urine     : 55–60
  • Volume of distribution (L/kg)       : 0.9–1.5
  • half-life – normal/ESRD (hrs)      : 16–20/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : 50% of normal parenteral dose. Other routes Dose as in normal renal function
  • 10 to 20     : 50% of normal parenteral dose. Other routes. Dose as in normal renal function
  • <10           : Avoid parenteral dose. Other routes Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Likely dialysability. Dose as in GFR <10 mL/min
  • HD                     : Likely dialysability. Dose as in GFR <10 mL/min
  • HDF/high flux   : Likely dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      : Likely dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs Effect may be diminished by beta-blockers Theophylline: increased risk of hypokalaemia

    ADMINISTRATION

    Reconstition

    –

    Route

    IV, SC, IM, oral, inhaled, nebulised

    Rate of Administration

    1.5–5 mcg/minute

    Comments

    For

    IV infusion

    , add 1.5–2.5 mg to 500 mL glucose 5% or sodium chloride 0.9% (3–5 micrograms/mL)

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia